Visualitza per autor "Castellano, D."
Ara mostrant els elements 1-4 d 4
-
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
de Wit, R.; Wülfing, C.; Castellano, D.; Kramer, G.; Eymard, J.-C.; Sternberg, C. N.; Carles Galceran, Joan (Elsevier, 2021-10) -
Cabozantinib for the treatment of solid tumors: a systematic review
Maroto, P.; Apolo, Andrea B.; Viteri Ramirez, Santiago; Martin, Lidia; Castellano, D.; Capdevila Castillon, Jaume; Porta, Camillo; Rodriguez-Antona, Cristina (SAGE Publications, 2022-07-13) -
Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study
Longo-Muñoz, Federico; Castellano, D.; Alexandre, Jerome; Chawla, Sant P.; Fernández, Cristian; Kahatt, Carmen; Sanz Garcia, Enrique (Elsevier, 2022-09) -
Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy
Alonso-Gordoa, Teresa; Reig Torras, Oscar; Esteban, Emilio ; Castellano, D.; Garcia del Muro, Xavier; González Rodríguez, Macarena; Grande, Enrique (Elsevier, 2022-04)